Maire F, Cibot JO, Compagne C, Hentic O, Hammel P, Muller N, Ponsot P, Levy P, Ruszniewski P.
Eur J Gastroenterol Hepatol. 2017 Aug;29(8):904-908.
Kleef J, Whitcomb DC, Shimosegawa T, Esposito I, Lerch MM, Gress T, Mayerle J, Drewes AM, Rebours V, Akisik F, Muñoz JED, Neoptolemos JP.
2017 Sep 7;3:17060.
Bucau M, Laurent-Bellue A, Poté N, Hentic O, Cros J, Mikail N, Rebours V, Ruszniewski P, Lebtahi R, Couvelard A.
Neuroendocrinology. 2017 Aug 11.
Lorenzo D, Maire F, Stefanescu C, Gornet JM, Seksik P, Serrero M, Bournet B, Marteau P, Amiot A, Laharie D, Trang C, Coffin B, Bellaiche G, Cadiot G, Reenaers C, Racine A, Viennot S, Pauwels A, Bouguen G, Savoye G, Pelletier AL, Pineton de Chambrun G, Lahmek P, Nahon S, Abitbol V; GETAID-AIP study group.
Clin Gastroenterol Hepatol. 2017 Aug 4.
Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms.
de Mestier L, Cros J, Neuzillet C, Hentic O, Egal A, Muller N, Bouché O, Cadiot G, Ruszniewski P, Couvelard A, Hammel P.
Neuroendocrinology. 2017;105(4):412-425. doi: 10.1159/000475527. Epub 2017 Aug 12. Review.
First Case of Radiation-Induced Diffuse Hemorrhagic Gastritis Successfully Treated with Intravenous Bevazicumab.
Maire F, Muller N, Lévy P.
Am J Gastroenterol. 2017 Aug;112(8):1349-1350.
Genome-wide association study identifies inversion in the CTRB1-CTRB2 locus to modify risk for alcoholic and non-alcoholic chronic pancreatitis.
Rosendahl J, Kirsten H, Hegyi E, Kovacs P, Weiss FU, Laumen H, Lichtner P, Ruffert C, Chen JM, Masson E, Beer S, Zimmer C, Seltsam K, Algül H, Bühler F, Bruno MJ, Bugert P, Burkhardt R, Cavestro GM, Cichoz-Lach H, Farré A, Frank J, Gambaro G, Gimpfl S, Grallert H, Griesmann H, Grützmann R, Hellerbrand C, Hegyi P, Hollenbach M, Iordache S, Jurkowska G, Keim V, Kiefer F, Krug S, Landt O, Leo MD, Lerch MM, Lévy P, Löffler M, Löhr M, Ludwig M, Macek M, Malats N, Malecka-Panas E, Malerba G, Mann K, Mayerle J, Mohr S, Te Morsche RHM, Motyka M, Mueller S, Müller T, Nöthen MM, Pedrazzoli S, Pereira SP, Peters A, Pfützer R, Real FX, Rebours V, Ridinger M, Rietschel M, Rösmann E, Saftoiu A, Schneider A, Schulz HU, Soranzo N, Soyka M, Simon P, Skipworth J, Stickel F, Strauch K, Stumvoll M, Testoni PA, Tönjes A, Werner L, Werner J, Wodarz N, Ziegler M, Masamune A, Mössner J, Férec C, Michl P, P H Drenth J, Witt H, Scholz M, Sahin-Tóth M; all members of the PanEuropean Working group on ACP.
Gut. 2017 Jul 28.
Acinar-to-Ductal Metaplasia Induced by Transforming Growth Factor Beta Facilitates KRASG12D-driven Pancreatic Tumorigenesis.
Chuvin N, Vincent DF, Pommier RM, Alcaraz LB, Gout J, Caligaris C, Yacoub K, Cardot V, Roger E, Kaniewski B, Martel S, Cintas C, Goddard-Léon S, Colombe A, Valantin J, Gadot N, Servoz E, Morton J, Goddard I, Couvelard A, Rebours V, Guillermet J, Sansom OJ, Treilleux I, Valcourt U, Sentis S, Dubus P, Bartholin L.
Cell Mol Gastroenterol Hepatol. 2017 May 31;4(2):263-282.
Estimation of the prevalence of intraductal papillary mucinous neoplasm of the pancreas in the French population through patients waiting for liver transplantation.
Laurent L, Vullierme MP, Rebours V, Maire F, Hentic O, Francoz C, Durand F, Ruszniewski P, Lévy P.
United European Gastroenterol J. 2017 Jun;5(4):499-503.
Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study.
Duell EJ, Lujan-Barroso L, Sala N, Deitz McElyea S, Overvad K, Tjonneland A, Olsen A, Weiderpass E, Busund LT, Moi L, Muller D, Vineis P, Aune D, Matullo G, Naccarati A, Panico S, Tagliabue G, Tumino R, Palli D, Kaaks R, Katzke VA, Boeing H, Bueno-de-Mesquita HBA, Peeters PH, Trichopoulou A, Lagiou P, Kotanidou A, Travis RC, Wareham N, Khaw KT, Quiros JR, Rodríguez-Barranco M, Dorronsoro M, Chirlaque MD, Ardanaz E, Severi G, Boutron-Ruault MC, Rebours V, Brennan P, Gunter M, Scelo G, Cote G, Sherman S, Korc M.
Int J Cancer. 2017 May 19.
United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU).
Löhr JM, Dominguez-Munoz E, Rosendahl J, Besselink M, Mayerle J, Lerch MM, Haas S, Akisik F, Kartalis N, Iglesias-Garcia J, Keller J, Boermeester M, Werner J, Dumonceau JM, Fockens P, Drewes A, Ceyhan G, Lindkvist B, Drenth J, Ewald N, Hardt P, de Madaria E, Witt H, Schneider A, Manfredi R, Brøndum FJ, Rudolf S, Bollen T, Bruno M; HaPanEU/UEG Working Group.
United European Gastroenterol J. 2017 Mar;5(2):153-199.
Epidemiology of pancreatic cancer in France: descriptive study from the French national hospital database.
Maire F, Cibot JO, Compagne C, Hentic O, Hammel P, Muller N, Ponsot P, Levy P, Ruszniewski P.
Eur J Gastroenterol Hepatol 2017;29:904-908.
NETTER-1 Trial Investigators. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O’Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R,Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M,Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E.
N Engl J Med. 2017 Jan 12;376(2):125-135.
Scoazec JY, Couvelard A; Réseau TENpath.
Ann Pathol. 2017 Dec;37(6):444-456.
Tumor Heterogeneity in Pancreatic Adenocarcinoma.
Cros J, Raffenne J, Couvelard A, Poté N.
Pathobiology. 2018;85(1-2):64-71.
A gastric MANEC with an adenocarcinoma of fundic-gland type as exocrine component. Nassereddine H, Poté N, Théou-Anton N, Lamoureux G, Fléjou JF, Couvelard A.
Virchows Arch. 2017 Nov;471(5):673-678.
Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, Borbath I, Cwikla J, Toumpanakis C, Kaltsas G, Davies P, Hörsch D, Tiensuu Janson E, Ramage J; Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology. 2017;105(3):295-309.
Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy.
Garcia-Carbonero R, Rinke A, Valle JW, Fazio N, Caplin M, Gorbounova V, O Connor J, Eriksson B, Sorbye H, Kulke M, Chen J, Falkerby J, Costa F, de Herder W, Lombard-Bohas C, Pavel M; Neuroendocrinology. 2017;105(3):281-294.
Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, Fazio N, Giammarile F, Hicks RJ, Kjaer A, Krenning E, Kwekkeboom D, Lombard-Bohas C, O’Connor JM, O’Toole D, Rockall A, Wiedenmann B, Valle JW, Vullierme MP;
Neuroendocrinology. 2017;105(3):212-244.
Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy – Biotherapy and Novel Targeted Agents.
Pavel M, Valle JW, Eriksson B, Rinke A, Caplin M, Chen J, Costa F, Falkerby J, Fazio N, Gorbounova V, de Herder W, Kulke M, Lombard-Bohas C, O’Connor J, Sorbye H, Garcia-Carbonero R; Antibes Consensus Conference Participants;
Neuroendocrinology. 2017;105(3):266-280.
Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors.
Kaltsas G, Caplin M, Davies P, Ferone D, Garcia-Carbonero R, Grozinsky-Glasberg S, Hörsch D, Tiensuu Janson E, Kianmanesh R, Kos-Kudla B, Pavel M, Rinke A, Falconi M, de Herder WW;
Neuroendocrinology. 2017;105(3):245-254.
Antibes Consensus Conference Participants; Antibes Consensus Conference participants. ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation.
Knigge U, Capdevila J, Bartsch DK, Baudin E, Falkerby J, Kianmanesh R, Kos-Kudla B, Niederle B, Nieveen van Dijkum E, O’Toole D, Pascher A, Reed N, Sundin A, Vullierme MP;
Neuroendocrinology. 2017;105(3):310-319.
Antibes Consensus Conference participants. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification. Perren A, Couvelard A, Scoazec JY, Costa F, Borbath I, Delle Fave G, Gorbounova V, Gross D, Grossma A, Jense RT, Kulke M, Oeberg K, Rindi G, Sorbye H, Welin S;
Neuroendocrinology. 2017;105(3):196-200.
Impact of Orexin-A Treatment on Food Intake, Energy Metabolism and Body Weight in Mice.
Blais A, Drouin G, Chaumontet C, Voisin T, Couvelard A, Even PC, Couvineau A.
PLoS One. 2017 Jan 13;12(1):e0169908.
Scoazec JY, Couvelard A, Monges G, Guyétant S, Bisot-Locard S, Parot X, Lepage C; PRONET Study Group.
Neuroendocrinology. 2017;105(1):67-76.
de Mestier L, Zappa M, Hentic O, Vilgrain V, Ruszniewski P. Liver transarterial embolizations in metastatic neuroendocrine tumors. Rev Endocr Metab Disord. 2017 Dec;18(4):459-471. doi: 10.1007/s11154-017-9431-2. Review. PubMed
PMID: 28975561.
Renard Y, de Mestier L, Perez M, Avisse C, Lévy P, Kianmanesh R. Unraveling Pancreatic Segmentation. World J Surg. 2018 Apr;42(4):1147-1153. doi: 10.1007/s00268-017-4263-5. Review. PubMed PMID: 28975436.
Neuzillet C, de Mestier L, Rousseau B, Mir O, Hebbar M, Kocher HM, Ruszniewski P, Tournigand C. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. Pharmacol Ther. 2018 Jan;181:49-75. doi: 10.1016/j.pharmthera.2017.07.006. Epub 2017 Jul 16. Review. PubMed PMID: 28723416.
de Mestier L, Cros J, Hammel P. 5-Fluorouracil biomarkers in pancreatic neuroendocrine tumours. Pancreatology. 2017 Jul – Aug;17(4):527-528. doi: 10.1016/j.pan.2017.06.004. Epub 2017 Jun 8. PubMed PMID: 28619285.
Vienot A, Beinse G, Louvet C, de Mestier L, Meurisse A, Fein F, Heyd B, Cleau D, d’Engremont C, Dupont-Gossart AC, Lakkis Z, Tournigand C, Bouché O, Rousseau B, Neuzillet C, Bonnetain F, Borg C, Vernerey D. Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx037. PubMed PMID: 28383673.
Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
Walter T, Tougeron D, Baudin E, Le Malicot K, Lecomte T, Malka D, Hentic O, Manfredi S, Bonnet I, Guimbaud R, Coriat R, Lepère C, Desauw C, Thirot-Bidault A, Dahan L, Roquin G, Aparicio T, Legoux JL, Lombard-Bohas C, Scoazec JY, Lepage C, Cadiot G; CEPD investigators.
Eur J Cancer. 2017 Jul;79:158-165. doi: 10.1016/j.ejca.2017.04.009. Epub 2017 May 11.
PMID: 28501762
Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.
Lepage C, Dahan L, Bouarioua N, Toumpanakis C, Legoux JL, Le Malicot K, Guimbaud R, Smith D, Tougeron D, Lievre A, Cadiot G, Di Fiore F, Bouhier-Leporrier K, Hentic O, Faroux R, Pavel M, Borbath I, Valle JW, Rinke A, Scoazec JY, Ducreux M, Walter T.
Dig Liver Dis. 2017 May;49(5):568-571. doi: 10.1016/j.dld.2017.02.004. Epub 2017 Mar 11.
PMID: 28292641
Neuroendocrine liver metastases: Vascular patterns on triple-phase MDCT are indicative of primary tumour location.
Ronot M, Cuccioli F, Dioguardi Burgio M, Vullierme MP, Hentic O, Ruszniewski P, d’Assignies G, Vilgrain V.
Eur J Radiol. 2017 Apr;89:156-162. doi: 10.1016/j.ejrad.2017.02.007. Epub 2017 Feb 9.
PMID: 28267533
Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE).
Roquin G, Baudin E, Lombard-Bohas C, Cadiot G, Dominguez S, Guimbaud R, Niccoli P, Legoux JL, Mitry E, Rohmer V, Ruszniewski P, Walter T, Ducreux M, Couvelard A, Scoazec JY, Ramond-Roquin A, Caroli-Bosc FX, Hentic O.
Neuroendocrinology. 2018;106(1):38-46. doi: 10.1159/000457955. Epub 2017 Feb 3.
PMID: 28152531
Is visual radiological evaluation of liver tumour burden in patients with neuroendocrine tumours reproducible?
Zappa M, Hentic O, Vullierme MP, Lagadec M, Ronot M, Ruszniewski P, Vilgrain V.
Endocr Connect. 2017 Jan;6(1):33-38. doi: 10.1530/EC-16-0092. Epub 2017 Jan 9.
PMID: 28069898
Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging.
Lotfalizadeh E, Ronot M, Wagner M, Cros J, Couvelard A, Vullierme MP, Allaham W, Hentic O, Ruzniewski P, Vilgrain V.
Eur Radiol. 2017 Apr;27(4):1748-1759. doi: 10.1007/s00330-016-4539-4. Epub 2016 Aug 19.
MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.
Cros J, Hentic O, Rebours V, Zappa M, Gille N, Theou-Anton N, Vernerey D, Maire F, Lévy P, Bedossa P, Paradis V, Hammel P, Ruszniewski P, Couvelard A.
Endocr Relat Cancer. 2016 Aug;23(8):625-33. doi: 10.1530/ERC-16-0117. Epub 2016 Jun 28.
PMID: 27353036
Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.
Sebbagh S, Roux J, Dreyer C, Neuzillet C, de Gramont A, Orbegoso C, Hentic O, Hammel P, de Gramont A, Raymond E, André T, Chibaudel B, Faivre S.
Acta Oncol. 2016 Sep – Oct;55(9-10):1168-1174. doi: 10.1080/0284186X.2016.1191670. Epub 2016 Jun 22.
PMID: 27333436
Unmet needs in the international neuroendocrine tumor (NET) community: assessment of major gaps from the perspective of patients, patient advocates and NET healthcare professionals.
Leyden S, Kolarova T, Bouvier C, Caplin M, Conroy S, Davies P, Dureja S, Falconi M, Ferolla P, Fisher G, Goldstein G, Hicks RJ, Lawrence B, Majima Y, Metz DC, O’Toole D, Ruszniewski P, Wiedenmann B, Hollander R; International Neuroendocrine Cancer Alliance (INCA).
Int J Cancer. 2019 Sep 11. doi: 10.1002/ijc.32678. [Epub ahead of print]
PMID: 31509608